@VivekSubbiah presenting at #asco2023 that prior single gene testing limits the performance of CGP and negatively impacts CGP turn around time and the identification of therapeutically relevant genomic variants in #NSCLC. Performing tissue based CGP is standard of care. @Labcorp
One more week until our live Ask the Expert Q&A with @Labcorp's @BeccaPrevisMD! Join us to learn how #personalized#medicine is transforming #breastcancer treatment and explore emerging targeted therapies for HER2-low breast cancer subtypes: https://t.co/n7MYfPeAID
Want to learn more about HER2-low breast cancer? Please tune into this webinar by my amazing colleague and oncologist, Dr. @BeccaPrevisMD as she leads important discussions around HER2-low breast cancer! 🙌🏻
Checkpoint inhibition has had limited efficacy in high grade epithelial cancer. So proud of @pammiepeters and her work evaluating MEM-288, a novel oncolytic adenovirus, demonstrating efficacy and generating a systemic immune response. #SGOMtg@dukeobgyn#PatientsPurposeProgress
Our fellow Pamela Peters discussing her work on MEM-288 under mentor @BeccaPrevisMD proud of her work to improve the understanding of ovarian cancer immune response @dukeobgyn
Congrats to @DukeMedSchool’s @LindaM_Zambrano and her important work highlighting funding to lethality scores in patients with cancer. Despite its increase in mortality, #uterinecancer remains underfunded. This work informs policy change, advocacy and equitable funding. #sgomtg
Thanks to everyone who attended our @Labcorp Case Study presentation where we reviewed the clinical, morphologic, cytogenetic, and #molecular characteristics of a case with a TP53 biallelic alteration. #ASH22@ASH_hematology